Cargando…

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma

BACKGROUND: Currently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT)....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lei, Wei, Xiu-feng, Li, Can-jun, Yang, Zhao-yang, Yu, Yong-kui, Li, Hao-miao, Xie, Hou-nai, Yang, Ya-fan, Jing, Wei-wei, Wang, Zhen, Kang, Xiao-zheng, Zhang, Rui-xiang, Qin, Jian-jun, Xue, Li-yan, Bi, Nan, Chen, Xian-kai, Li, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713810/
https://www.ncbi.nlm.nih.gov/pubmed/36466925
http://dx.doi.org/10.3389/fimmu.2022.1052542
_version_ 1784842092571262976
author Xu, Lei
Wei, Xiu-feng
Li, Can-jun
Yang, Zhao-yang
Yu, Yong-kui
Li, Hao-miao
Xie, Hou-nai
Yang, Ya-fan
Jing, Wei-wei
Wang, Zhen
Kang, Xiao-zheng
Zhang, Rui-xiang
Qin, Jian-jun
Xue, Li-yan
Bi, Nan
Chen, Xian-kai
Li, Yin
author_facet Xu, Lei
Wei, Xiu-feng
Li, Can-jun
Yang, Zhao-yang
Yu, Yong-kui
Li, Hao-miao
Xie, Hou-nai
Yang, Ya-fan
Jing, Wei-wei
Wang, Zhen
Kang, Xiao-zheng
Zhang, Rui-xiang
Qin, Jian-jun
Xue, Li-yan
Bi, Nan
Chen, Xian-kai
Li, Yin
author_sort Xu, Lei
collection PubMed
description BACKGROUND: Currently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT). Our study aimed to compare treatment response and postoperative complications after NICT followed by surgery with that after conventional NCRT in patients with locally advanced ESCC. METHODS: Of 468 patients with locally advanced ESCC, 154 received conventional NCRT, whereas 314 received NICT. Treatment response, postoperative complications and mortality between two groups were compared. Pathological response of primary tumor was evaluated using the Mandard tumor regression grade (TRG) scoring system. Pathological complete response (pCR) of metastatic lymph nodes (LNs) was defined as no viable tumor cell within all resected metastatic LNs. According to regression directionality, tumor regression pattern was summarized into four categories: type I, regression toward the lumen; type II, regression toward the invasive front; type III, concentric regression; and type IV, scattered regression. Inverse probability propensity score weighting was performed to minimize the influence of confounding factors. RESULTS: After adjusting for baseline characteristics, the R0 resection rates (90.9% vs. 89.0%, P=0.302) and pCR (ypT0N0) rates (29.8% vs. 34.0%, P=0.167) were comparable between two groups. Patients receiving NCRT showed lower TRG score (P<0.001) and higher major pathological response (MPR) rate (64.7% vs. 53.6%, P=0.001) compared to those receiving NICT. However, NICT brought a higher pCR rate of metastatic LNs than conventional NCRT (53.9% vs. 37.1%, P<0.001). The rates of type I/II/III/IV regression patterns were 44.6%, 6.8%, 11.4% and 37.1% in the NICT group, 16.9%, 8.2%, 18.3% and 56.6% in the NCRT group, indicating a significant difference (P<0.001). Moreover, there were no significant differences in the incidence of total postoperative complications (35.8% vs. 39.9%, P=0.189) and 30-d mortality (0.0% vs. 1.1%, P=0.062). CONCLUSION: For patients with locally advanced ESCC, NICT showed a R0 resection rate and pCR (ypT0N0) rate comparable to conventional NCRT, without increased incidence of postoperative complications and mortality. Notablely, NICT followed by surgery might bring a promising treatment response of metastatic LNs.
format Online
Article
Text
id pubmed-9713810
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97138102022-12-02 Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma Xu, Lei Wei, Xiu-feng Li, Can-jun Yang, Zhao-yang Yu, Yong-kui Li, Hao-miao Xie, Hou-nai Yang, Ya-fan Jing, Wei-wei Wang, Zhen Kang, Xiao-zheng Zhang, Rui-xiang Qin, Jian-jun Xue, Li-yan Bi, Nan Chen, Xian-kai Li, Yin Front Immunol Immunology BACKGROUND: Currently, the role of immunotherapy in neoadjuvant setting for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is gradually attracting attention. Few studies compared the efficacy of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT). Our study aimed to compare treatment response and postoperative complications after NICT followed by surgery with that after conventional NCRT in patients with locally advanced ESCC. METHODS: Of 468 patients with locally advanced ESCC, 154 received conventional NCRT, whereas 314 received NICT. Treatment response, postoperative complications and mortality between two groups were compared. Pathological response of primary tumor was evaluated using the Mandard tumor regression grade (TRG) scoring system. Pathological complete response (pCR) of metastatic lymph nodes (LNs) was defined as no viable tumor cell within all resected metastatic LNs. According to regression directionality, tumor regression pattern was summarized into four categories: type I, regression toward the lumen; type II, regression toward the invasive front; type III, concentric regression; and type IV, scattered regression. Inverse probability propensity score weighting was performed to minimize the influence of confounding factors. RESULTS: After adjusting for baseline characteristics, the R0 resection rates (90.9% vs. 89.0%, P=0.302) and pCR (ypT0N0) rates (29.8% vs. 34.0%, P=0.167) were comparable between two groups. Patients receiving NCRT showed lower TRG score (P<0.001) and higher major pathological response (MPR) rate (64.7% vs. 53.6%, P=0.001) compared to those receiving NICT. However, NICT brought a higher pCR rate of metastatic LNs than conventional NCRT (53.9% vs. 37.1%, P<0.001). The rates of type I/II/III/IV regression patterns were 44.6%, 6.8%, 11.4% and 37.1% in the NICT group, 16.9%, 8.2%, 18.3% and 56.6% in the NCRT group, indicating a significant difference (P<0.001). Moreover, there were no significant differences in the incidence of total postoperative complications (35.8% vs. 39.9%, P=0.189) and 30-d mortality (0.0% vs. 1.1%, P=0.062). CONCLUSION: For patients with locally advanced ESCC, NICT showed a R0 resection rate and pCR (ypT0N0) rate comparable to conventional NCRT, without increased incidence of postoperative complications and mortality. Notablely, NICT followed by surgery might bring a promising treatment response of metastatic LNs. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9713810/ /pubmed/36466925 http://dx.doi.org/10.3389/fimmu.2022.1052542 Text en Copyright © 2022 Xu, Wei, Li, Yang, Yu, Li, Xie, Yang, Jing, Wang, Kang, Zhang, Qin, Xue, Bi, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xu, Lei
Wei, Xiu-feng
Li, Can-jun
Yang, Zhao-yang
Yu, Yong-kui
Li, Hao-miao
Xie, Hou-nai
Yang, Ya-fan
Jing, Wei-wei
Wang, Zhen
Kang, Xiao-zheng
Zhang, Rui-xiang
Qin, Jian-jun
Xue, Li-yan
Bi, Nan
Chen, Xian-kai
Li, Yin
Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
title Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
title_full Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
title_fullStr Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
title_full_unstemmed Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
title_short Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
title_sort pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713810/
https://www.ncbi.nlm.nih.gov/pubmed/36466925
http://dx.doi.org/10.3389/fimmu.2022.1052542
work_keys_str_mv AT xulei pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT weixiufeng pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT licanjun pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT yangzhaoyang pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT yuyongkui pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT lihaomiao pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT xiehounai pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT yangyafan pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT jingweiwei pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT wangzhen pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT kangxiaozheng pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT zhangruixiang pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT qinjianjun pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT xueliyan pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT binan pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT chenxiankai pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma
AT liyin pathologicresponsesandsurgicaloutcomesafterneoadjuvantimmunochemotherapyversusneoadjuvantchemoradiotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinoma